Susan E Clare
Overview
Explore the profile of Susan E Clare including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1309
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hajirahimkhan A, Bartom E, Chung C, Guo X, Berkley K, Lee O, et al.
bioRxiv
. 2024 Dec;
PMID: 39651211
Background: Anti-estrogens have had limited impact on breast cancer (BC) prevention. Novel agents with better tolerability, and efficacy beyond estrogen receptor (ER) positive BC are needed. We studied licochalcone A...
2.
Hajirahimkhan A, Howell C, Bartom E, Dong H, Lantvit D, Xuei X, et al.
Sci Rep
. 2023 May;
13(1):8734.
PMID: 37253812
Breast cancer risk continues to increase post menopause. Anti-estrogen therapies are available to prevent postmenopausal breast cancer in high-risk women. However, their adverse effects have reduced acceptability and overall success...
3.
Yadav S, Virk R, Chung C, Bustamante Eduardo M, VanDerway D, Chen D, et al.
NPJ Breast Cancer
. 2023 Mar;
9(1):11.
PMID: 36914690
No abstract available.
4.
Yadav S, Virk R, Chung C, Bustamante Eduardo M, VanDerway D, Chen D, et al.
NPJ Breast Cancer
. 2022 May;
8(1):59.
PMID: 35508495
Improved understanding of local breast biology that favors the development of estrogen receptor negative (ER-) breast cancer (BC) would foster better prevention strategies. We have previously shown that overexpression of...
5.
Zeng Z, Mao C, Vo A, Li X, Nugent J, Khan S, et al.
BMC Bioinformatics
. 2021 Oct;
22(Suppl 4):491.
PMID: 34689757
Background: Genetic information is becoming more readily available and is increasingly being used to predict patient cancer types as well as their subtypes. Most classification methods thus far utilize somatic...
6.
Ranjan M, Lee O, Cottone G, Mehrabad E, Spike B, Zeng Z, et al.
Breast Cancer Res
. 2021 Aug;
23(1):78.
PMID: 34344445
Background: The ovarian hormones estrogen and progesterone (EP) are implicated in breast cancer causation. A specific consequence of progesterone exposure is the expansion of the mammary stem cell (MSC) and...
7.
Lee O, Bosland M, Wang M, Shidfar A, Hosseini O, Xuei X, et al.
Cancer Lett
. 2021 Jul;
520:255-266.
PMID: 34329741
Pharmacological approaches to breast cancer risk-reduction for BRCA1 mutation carriers would provide an alternative to mastectomy. BRCA1-deficiency dysregulates progesterone signaling, promoting tumorigenesis. Selective progesterone receptor (PR) modulators (SPRMs) are therefore...
8.
Zeng Z, Yao L, Roy A, Li X, Espino S, Clare S, et al.
J Healthc Inform Res
. 2020 Nov;
3:283-299.
PMID: 33225204
Accurately identifying distant recurrences in breast cancer from the Electronic Health Records (EHR) is important for both clinical care and secondary analysis. Although multiple applications have been developed for computational...
9.
Bodelon C, Oh H, Derkach A, Sampson J, Sprague B, Vacek P, et al.
NPJ Breast Cancer
. 2020 Sep;
6:41.
PMID: 32964115
Terminal duct lobular units (TDLUs) are the predominant anatomical structures where breast cancers originate. Having lesser degrees of age-related TDLU involution, measured as higher TDLUs counts or more epithelial TDLU...
10.
Zeng Z, Vo A, Li X, Shidfar A, Saldana P, Blanco L, et al.
NPJ Breast Cancer
. 2020 Jun;
6:24.
PMID: 32566745
It is largely unknown how the development of breast cancer (BC) is transduced by somatic genetic alterations in the benign breast. Since benign breast disease is an established risk factor...